When Investors Make Decisions in Teva Pharmaceutical Industries Limited American Depositary Shares TEVA Opportunities Surface ...

The most notable increase was Teva Pharmaceutical Industries Ltd (NYSE:TEVA), with an additional 7,569,450 shares, bringing the total to 8,997,400 shares. This adjustment represents a significant 530.

Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), recently sold a substantial block of the company's ordinary shares. The ...

The Sound Shore Fund Investor Class (SSHFX) and Institutional Class (SSHVX) advanced 1.25% and 1.32%, respectively, in Q3 ...

Axsome Therapeutics, Inc.'s' stock surges 30% amid key catalysts. Learn why it's now rated a Buy wih upcoming data opportunities. Click for my AXSM update.

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Shares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement ...

TD Cowen raised the firm’s price target on Axsome Therapeutics (AXSM) to $190 from $155 and keeps a Buy rating on the shares. The company ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...

Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...

Axsome settles Auvelity patent litigation with Teva, delaying a generic launch until 2038. Analysts see growth potential with Symbravo's migraine approval.